Dias-Santagata, Dora

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 3,499

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC

Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,059

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 1,022

Frequent Mutation of Isocitrate Dehydrogenase(IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 728

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine

Cancer Genomics and DiagnosticsColorectal Cancer Treatments and Studies

Cited by 518

EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 500

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Ohashi, K., Sequist, L. V., Arcila, M. E., Moran, T., Chmielecki, J., Lin, Y.-L., Pan, Y., Wang, L., de Stanchina, E., Shien, K., et al. (2012) · Proceedings of the National Academy of Sciences

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 441

Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience

Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 430

The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy

Scherz-Shouval, R., Santagata, S., Mendillo, M. L., Sholl, L. M., Ben-Aharon, I., Beck, A. H., Dias-Santagata, D., Koeva, M., Stemmer, S. M., Whitesell, L., et al. (2014) · Cell

Heat shock proteins researchTGF-β signaling in diseases

Cited by 386

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 377

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 370

BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation

Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 350

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF -Mutant Colorectal Cancer through MAPK Pathway Alterations

Ahronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 322

Oxidative stress mediates tau-induced neurodegeneration in Drosophila

Dias-Santagata, D., Fulga, T. A., Duttaroy, A., & Feany, M. B. (2007) · Journal of Clinical Investigation

Alzheimer's disease research and treatmentsRedox biology and oxidative stress

Cited by 318

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery

Lung Cancer Treatments and MutationsCell death mechanisms and regulation

Cited by 283

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH -Mutant Gliomas

Wakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 190

Tau Phosphorylation Sites Work in Concert to Promote Neurotoxicity In Vivo

Steinhilb, M. L., Dias-Santagata, D., Fulga, T. A., Felch, D. L., & Feany, M. B. (2007) · Molecular Biology of the Cell

Alzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Cited by 187

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

Su, Z., Dias-Santagata, D., Duke, M., Hutchinson, K., Lin, Y.-L., Borger, D. R., Chung, C. H., Massion, P. P., Vnencak-Jones, C. L., Iafrate, A. J., et al. (2011) · The Journal of Molecular Diagnostics

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 176